Abbott Laboratories shares fall nearly 2% as net earnings and cash flow slip despite higher sales

Traders Union
All News
Stocks
Abbott Laboratories slides 1.87% today

Highlights

Abbott Laboratories reported third-quarter net sales of $13.013 billion, up from $11.369 billion a year earlier.
Net earnings dropped to $920 million and diluted earnings per share fell to $0.53, with operating cash flow for the first nine months at $5.54 billion.
Shares of Abbott trade in an established uptrend but multiple overbought indicators signal risk of a short-term pullback within the projected range of $108.02 to $118.78.

Sales growth offset by profit drop amid acquisition and legal costs

Abbott Laboratories reported third-quarter 2026 net sales of $13.013 billion, up from $11.369 billion in the prior year. Net earnings fell to $920 million and diluted earnings per share decreased to $0.53. Operating cash flow for the first nine months of 2026 declined to $5.54 billion. The company declared quarterly dividends of $0.63 per share, representing a 6.8% increase from the prior year, and completed the $20.6 billion acquisition of Exact Sciences in March 2026 while progressing on integration and managing legal liabilities. These developments unfolded as price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees persistent risks in Abbott's outlook as earnings and cash flow drop despite headline revenue growth. The ongoing integration of Exact Sciences and higher dividend payouts may raise future pressure on margins. Technically, he notes overbought oscillators hint at vulnerability, with ABT now near key support of $113.06. Sentiment remains weak as broader selling lingers and high volatility tests investor conviction. "The warning signs in both fundamentals and chart structure suggest traders should stay defensive until genuine reversal signals emerge."

Viktoras Karapetjanc, expert at Traders Union, highlights the robust sales growth and successful integration of Exact Sciences as key positives. He believes the higher dividend and sustained progress on synergies reflect management’s confidence in long-term prospects. Despite short-term volatility and oscillators flashing overbought, Karapetjanc notes that the bullish structure remains intact above $113.06. "Market offers multiple setups for further growth, especially if resistance at $116.18 is broken."

Sholanke Dele, market strategist, is cautious about the sharp fall in net earnings and declining operating cash flow. He notes that legal risks and integration challenges might weigh on sentiment even as the company posts higher sales. Dele warns that high volatility and stretched technicals can fuel uncertainty in the short term. "Traders should watch for a break below $113.06, as a failure here could accelerate downside pressure."

Momentum strong as technicals signal bullish bias with overbought risk

ABT is trading above its 20-day, 50-day, and 200-day moving averages ($104.26, $104.06, and $101.54), confirming bullish trends across all key time frames. The nearest resistance stands at $116.18 while support is observed at $113.06, with the Ichimoku Kijun at $105.76 backing the established uptrend. Momentum remains strong, as highlighted by a positive MACD and Average Directional Index, alongside Bull/Bear Power (BBP) and the Awesome Oscillator both confirming buyer dominance. However, the Relative Strength Index (RSI), Stochastic RSI, and Commodity Channel Index (CCI) are each in overbought territory, signaling elevated risks for a short-term correction. ABT trades near session lows with high intraday volatility, reflecting persistent buyer momentum but caution due to stretched oscillator readings.

Earlier, analysts noted that Abbott Laboratories had shifted into a bullish technical stance, supported by strong momentum and a decisive move above major moving averages. The current analysis affirms this positive trend but highlights the increased risk of short-term correction due to overbought oscillator readings, making the $116.18 resistance level the key threshold to monitor for breakout or reversal.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.